CR11439A - Composiciones para inhalacion comprendiendo acido montelukast y un inhibidor pde-4 o un corticosteroide inhalado - Google Patents
Composiciones para inhalacion comprendiendo acido montelukast y un inhibidor pde-4 o un corticosteroide inhaladoInfo
- Publication number
- CR11439A CR11439A CR11439A CR11439A CR11439A CR 11439 A CR11439 A CR 11439A CR 11439 A CR11439 A CR 11439A CR 11439 A CR11439 A CR 11439A CR 11439 A CR11439 A CR 11439A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pde
- inhalation
- inhibitor
- compositions
- understanding
- Prior art date
Links
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 title abstract 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 239000003246 corticosteroid Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229960005127 montelukast Drugs 0.000 title abstract 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32707P | 2007-10-25 | 2007-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR11439A true CR11439A (es) | 2010-06-21 |
Family
ID=40579006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR11439A CR11439A (es) | 2007-10-25 | 2010-05-18 | Composiciones para inhalacion comprendiendo acido montelukast y un inhibidor pde-4 o un corticosteroide inhalado |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100210611A1 (enExample) |
| EP (1) | EP2211863A4 (enExample) |
| JP (1) | JP2011500731A (enExample) |
| KR (1) | KR20100072295A (enExample) |
| CN (1) | CN101909626A (enExample) |
| AU (1) | AU2008316283A1 (enExample) |
| CA (1) | CA2701956A1 (enExample) |
| CO (1) | CO6270213A2 (enExample) |
| CR (1) | CR11439A (enExample) |
| DO (1) | DOP2010000122A (enExample) |
| GT (1) | GT201000107A (enExample) |
| IL (1) | IL205182A0 (enExample) |
| MA (1) | MA33705B1 (enExample) |
| MX (1) | MX2010004529A (enExample) |
| NI (1) | NI201000069A (enExample) |
| NZ (1) | NZ584876A (enExample) |
| RU (1) | RU2470639C2 (enExample) |
| WO (1) | WO2009052624A1 (enExample) |
| ZA (1) | ZA201002562B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012168907A1 (en) | 2011-06-10 | 2012-12-13 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising revamilast and montelukast or zafirlukast |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| JP2017503814A (ja) | 2014-01-22 | 2017-02-02 | タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療 |
| CN108267531B (zh) * | 2016-12-31 | 2022-01-11 | 天津金耀集团有限公司 | 一种环索奈德有关物质hplc测定方法 |
| IT201900014178A1 (it) * | 2019-08-06 | 2021-02-06 | Genetic S P A | Esteri del montelukast e loro formulazioni farmaceutiche |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| US20040214805A1 (en) * | 1999-11-02 | 2004-10-28 | Smithkline Beecham Corporation | Method and compositions for treating pulmonary diseases |
| CA2427814C (en) * | 2000-11-07 | 2009-06-02 | Merck & Co., Inc. | A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders |
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| WO2003024488A2 (en) * | 2001-09-19 | 2003-03-27 | Altana Pharma Ag | Combination of a pde inhibitor and a leukotriene receptor antagonist |
| DE10237739A1 (de) * | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| ES2452691T5 (es) * | 2003-09-16 | 2022-09-14 | Covis Pharma Gmbh | Uso de ciclesonida para el tratamiento de enfermedades respiratorias |
| AU2004283832B2 (en) * | 2003-10-10 | 2011-04-07 | Synthon B.V. | Solid-state montelukast |
| PL1713471T3 (pl) * | 2004-02-06 | 2012-06-29 | Meda Pharma Gmbh & Co Kg | Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| CA2595791C (en) * | 2005-03-16 | 2013-10-08 | Meda Pharma Gmbh & Co. Kg | The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases |
| EA200701987A1 (ru) * | 2005-03-16 | 2008-02-28 | Элан Фарма Интернэшнл Лтд. | Составы из нанодисперсного антагониста лейкотриеновых рецепторов/кортикостероида |
| WO2007036029A1 (en) * | 2005-09-28 | 2007-04-05 | Merck Frosst Canada Ltd. | Aerosol powder formulation comprising sieved lactose |
-
2008
- 2008-10-23 RU RU2010120806/15A patent/RU2470639C2/ru not_active IP Right Cessation
- 2008-10-23 NZ NZ584876A patent/NZ584876A/en not_active IP Right Cessation
- 2008-10-23 CN CN2008801225895A patent/CN101909626A/zh active Pending
- 2008-10-23 MX MX2010004529A patent/MX2010004529A/es not_active Application Discontinuation
- 2008-10-23 AU AU2008316283A patent/AU2008316283A1/en not_active Abandoned
- 2008-10-23 KR KR1020107009041A patent/KR20100072295A/ko not_active Withdrawn
- 2008-10-23 EP EP08842623A patent/EP2211863A4/en not_active Withdrawn
- 2008-10-23 JP JP2010530233A patent/JP2011500731A/ja active Pending
- 2008-10-23 US US12/738,946 patent/US20100210611A1/en not_active Abandoned
- 2008-10-23 CA CA2701956A patent/CA2701956A1/en not_active Abandoned
- 2008-10-23 WO PCT/CA2008/001874 patent/WO2009052624A1/en not_active Ceased
-
2010
- 2010-04-13 ZA ZA2010/02562A patent/ZA201002562B/en unknown
- 2010-04-18 IL IL205182A patent/IL205182A0/en unknown
- 2010-04-19 GT GT201000107A patent/GT201000107A/es unknown
- 2010-04-22 NI NI201000069A patent/NI201000069A/es unknown
- 2010-04-22 CO CO10047531A patent/CO6270213A2/es not_active Application Discontinuation
- 2010-04-23 DO DO2010000122A patent/DOP2010000122A/es unknown
- 2010-05-18 CR CR11439A patent/CR11439A/es not_active Application Discontinuation
- 2010-05-20 MA MA32860A patent/MA33705B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011500731A (ja) | 2011-01-06 |
| EP2211863A4 (en) | 2012-07-25 |
| CA2701956A1 (en) | 2009-04-30 |
| RU2010120806A (ru) | 2011-11-27 |
| NZ584876A (en) | 2012-06-29 |
| GT201000107A (es) | 2012-03-13 |
| MA33705B1 (fr) | 2012-11-01 |
| US20100210611A1 (en) | 2010-08-19 |
| ZA201002562B (en) | 2011-06-29 |
| RU2470639C2 (ru) | 2012-12-27 |
| CN101909626A (zh) | 2010-12-08 |
| IL205182A0 (en) | 2010-11-30 |
| AU2008316283A1 (en) | 2009-04-30 |
| WO2009052624A1 (en) | 2009-04-30 |
| WO2009052624A9 (en) | 2010-11-25 |
| DOP2010000122A (es) | 2010-07-15 |
| EP2211863A1 (en) | 2010-08-04 |
| CO6270213A2 (es) | 2011-04-20 |
| NI201000069A (es) | 2010-08-23 |
| KR20100072295A (ko) | 2010-06-30 |
| MX2010004529A (es) | 2010-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03347B (me) | PARAZITICIDNE KOMPOZICIJE KOJE SADRŽE IZOKSAZOLINSKO AKTIVNO SREDSTVO, POSTUPCI l UPOTREBE POVEZANE SA NJIMA | |
| BR112013012587A2 (pt) | composição farmacêutica para administração nasal | |
| PH12017501306A1 (en) | Inhibitors of histone demethylases | |
| BR112015029970A2 (pt) | inibidores de cinase | |
| CY1118034T1 (el) | Συνθεσεις για αναπνευστικη απελευθερωση ενεργων παραγοντων και συσχετιζομενες μεθοδοι και συστηματα | |
| NZ746271A (en) | Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof | |
| CL2012001971A1 (es) | Compuestos derivados de 1-piperazinil-3-piridin-carboxilato, como bloqueadores de los canales de sodio dependientes de voltaje; composicion farmaceutica; y su uso para el tratamiento de enfermedades respiratorias o del tracto respiratorio tal como asma, epoc, tos, silicosis, entre otras. | |
| AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
| BR112012032087A2 (pt) | composto, medicamento, e, uso de um composto | |
| NI201400046A (es) | AGENTES iARN, COMPOSICIONES Y MÉTODOS DE USO DE LOS MISMOS PARA TRATAR ENFERMEDADES ASOCIADAS CON TRANSTIRETINA (TTR) | |
| MX349802B (es) | Uso de aril- y hetarilcarboxamidas como endoparasiticidas. | |
| CL2012003450A1 (es) | Una formulacion en polvo seca inhalable que comprende como ingrediente activo particulas micronizadas de un compuesto antimuscarinico derivado de 1-azonia-biciclo[2.2.2]octano y particulas de un vehiculo; inhalador de polvo seco que la comprende, util para la prevencion y/o el tratamiento de una enfermedad respiratoria tal como asma y epoc. | |
| EA200900267A1 (ru) | КОМПОЗИЦИЯ ДЛЯ АЭРОЗОЛЬНОЙ ИНГАЛЯЦИИ β-АГОНИСТОВ И СТЕРОИДОВ | |
| CY1115109T1 (el) | Συνθεση αερολυματος για χαπ | |
| CL2014003503A1 (es) | Composición farmacéutica para uso intramamario que comprende un ácido fosfónico y al menos un agente antimicrobiano; y uso para el tratamiento o prevención de mastitis en mamífero no humano. | |
| NZ708821A (en) | Lfa-1 inhibitor formulations | |
| UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
| CR11439A (es) | Composiciones para inhalacion comprendiendo acido montelukast y un inhibidor pde-4 o un corticosteroide inhalado | |
| CR10350A (es) | Mezcla herbicida, que comprende un herbicida de imidazolinona y un adyuvante | |
| CR11419A (es) | Formulaciones de polvo seco que comprenden derivados del acido ascorbico | |
| WO2012104240A3 (de) | Kosmetische verwendung | |
| MX2010008852A (es) | Formulaciones de flibanserina. | |
| CR20130520A (es) | Composición herbicida que comprende flazasulfuron y metribuzina | |
| WO2013190497A3 (en) | Compositions and methods for treatment of inflammatory diseases of the lung | |
| BR112012027432A2 (pt) | composições farmacêuticas com agentes antimicrobianos de fosfônio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal (granting procedure) |